Trade Sensei Biotherapeutics, Inc. - SNSE CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Sensei Biotherapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 0.85-2.10 |
| Average Volume (10 days) | 15.14K |
| Average Volume (3 months) | 443.14K |
| Market Cap | 24.19M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 26.58M |
| Revenue | N/A |
| EPS | -1.47 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Sensei Biotherapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2023 Sensei Biotherapeutics Inc Earnings Release Q3 2023 Sensei Biotherapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 50.188 | 36.915 | 19.406 | 12.51 | 12.74 |
| Selling/General/Admin. Expenses, Total | 19.805 | 15.82 | 7.528 | 4.085 | 4.513 |
| Research & Development | 30.383 | 21.662 | 11.185 | 8.35 | 8.227 |
| Unusual Expense (Income) | 0 | -0.567 | 0.693 | 0.075 | 0 |
| Operating Income | -50.188 | -36.915 | -19.406 | -12.51 | -12.74 |
| Interest Income (Expense), Net Non-Operating | 1.564 | 0.13 | -0.694 | -4.229 | -0.327 |
| Other, Net | 0 | -0.001 | 0.028 | ||
| Net Income Before Taxes | -48.588 | -36.794 | -20.1 | -16.74 | -13.039 |
| Net Income After Taxes | -48.588 | -36.794 | -20.1 | -16.74 | -13.039 |
| Net Income Before Extra. Items | -48.588 | -36.794 | -20.1 | -16.74 | -13.039 |
| Net Income | -48.588 | -36.794 | -20.1 | -16.74 | -13.039 |
| Total Adjustments to Net Income | 0 | -0.104 | -3.804 | -3.804 | |
| Income Available to Common Excl. Extra. Items | -48.588 | -36.794 | -20.204 | -20.544 | -16.843 |
| Income Available to Common Incl. Extra. Items | -48.588 | -36.794 | -20.204 | -20.544 | -16.843 |
| Diluted Net Income | -48.588 | -36.794 | -20.204 | -20.544 | -16.843 |
| Diluted Weighted Average Shares | 30.7033 | 27.7107 | 29.5583 | 29.5583 | 29.5583 |
| Diluted EPS Excluding Extraordinary Items | -1.5825 | -1.32779 | -0.68353 | -0.69503 | -0.56982 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.58367 | -1.34793 | -0.66009 | -0.6925 | -0.56982 |
| Gain (Loss) on Sale of Assets | 0.036 | -0.009 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 10.177 | 11.008 | 13.048 | 13.941 | 10.712 |
| Selling/General/Admin. Expenses, Total | 5.393 | 5.804 | 5.703 | 4.751 | 4.319 |
| Research & Development | 4.784 | 5.204 | 7.345 | 9.19 | 6.393 |
| Operating Income | -10.177 | -11.008 | -13.048 | -13.941 | -10.712 |
| Interest Income (Expense), Net Non-Operating | 0.982 | 0.936 | 0.815 | 0.505 | 0.177 |
| Net Income Before Taxes | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 |
| Net Income After Taxes | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 |
| Net Income Before Extra. Items | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 |
| Net Income | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 |
| Total Adjustments to Net Income | |||||
| Income Available to Common Excl. Extra. Items | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 |
| Income Available to Common Incl. Extra. Items | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 |
| Diluted Net Income | -9.386 | -10.177 | -12.232 | -13.416 | -10.535 |
| Diluted Weighted Average Shares | 30.507 | 30.8661 | 30.7427 | 30.7203 | 30.7018 |
| Diluted EPS Excluding Extraordinary Items | -0.30767 | -0.32971 | -0.39788 | -0.43671 | -0.34314 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.30141 | -0.31983 | -0.39905 | -0.43671 | -0.34314 |
| Unusual Expense (Income) | 0 | 0 | |||
| Gain (Loss) on Sale of Assets | -0.191 | -0.105 | 0.036 | 0 | |
| Other, Net | -0.035 | 0.02 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 108.589 | 148.542 | 20.076 | 0.502 | 1.28 |
| Cash and Short Term Investments | 107.116 | 147.621 | 16.596 | 0.251 | 0.653 |
| Cash & Equivalents | 17.795 | 7.159 | 16.596 | 0.251 | 0.653 |
| Prepaid Expenses | 1.129 | 0.547 | 1.375 | 0.251 | 0.504 |
| Other Current Assets, Total | 0.344 | 0.374 | 2.105 | 0 | 0.123 |
| Total Assets | 118.375 | 153.225 | 21.428 | 1.217 | 1.85 |
| Property/Plant/Equipment, Total - Net | 9.723 | 4.644 | 1.266 | 0.268 | 0.123 |
| Property/Plant/Equipment, Total - Gross | 11.166 | 5.833 | 1.861 | 0.655 | 0.437 |
| Accumulated Depreciation, Total | -1.442 | -1.189 | -0.595 | -0.387 | -0.314 |
| Other Long Term Assets, Total | 0.063 | 0.039 | 0.086 | 0.447 | 0.447 |
| Total Current Liabilities | 9.066 | 4.889 | 4.83 | 21.714 | 2.663 |
| Accounts Payable | 3.451 | 1.108 | |||
| Accrued Expenses | 3.713 | 1.753 | 0.916 | 2.083 | 0.652 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.88 | 0.68 | 0 | 16.055 | 0.696 |
| Other Current Liabilities, Total | 0.032 | 0.125 | 0.207 | ||
| Total Liabilities | 14.968 | 6.712 | 5.535 | 22.334 | 7.785 |
| Total Long Term Debt | 1.579 | 1.674 | 0.567 | 0 | 4.05 |
| Long Term Debt | 0 | 0.567 | 0 | 4.05 | |
| Other Liabilities, Total | 4.323 | 0.149 | 0.138 | 0.62 | 1.072 |
| Total Equity | 103.407 | 146.513 | 15.893 | -21.117 | -5.935 |
| Redeemable Preferred Stock | 0 | 47.545 | 47.545 | ||
| Common Stock | 0.003 | 0.003 | 0.002 | 0.002 | |
| Additional Paid-In Capital | 302.202 | 296.049 | 55.969 | 23.648 | 22.09 |
| Retained Earnings (Accumulated Deficit) | -197.794 | -149.206 | -112.412 | -92.312 | -75.572 |
| Total Liabilities & Shareholders’ Equity | 118.375 | 153.225 | 21.428 | 1.217 | 1.85 |
| Total Common Shares Outstanding | 30.7642 | 30.609 | 30.5885 | 29.5583 | 29.5583 |
| Payable/Accrued | 4.473 | 2.456 | 3.882 | ||
| Preferred Stock - Non Redeemable, Net | 0 | 72.336 | |||
| Short Term Investments | 89.321 | 140.462 | |||
| Capital Lease Obligations | 1.579 | 1.674 | |||
| Other Equity, Total | -1.004 | -0.333 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 98.608 | 108.589 | 118.482 | 127.491 | 138.977 |
| Cash and Short Term Investments | 95.505 | 107.116 | 116.558 | 123.714 | 136.224 |
| Cash & Equivalents | 8.109 | 17.795 | 11.45 | 9.899 | 8.721 |
| Prepaid Expenses | 2.649 | 1.129 | 1.588 | 3.484 | 2.554 |
| Other Current Assets, Total | 0.454 | 0.344 | 0.336 | 0.293 | 0.199 |
| Total Assets | 107.933 | 118.375 | 128.803 | 138.036 | 150.038 |
| Property/Plant/Equipment, Total - Net | 9.244 | 9.723 | 10.276 | 10.5 | 11.022 |
| Property/Plant/Equipment, Total - Gross | 10.822 | 11.166 | 11.747 | 11.99 | 12.368 |
| Accumulated Depreciation, Total | -1.578 | -1.442 | -1.471 | -1.49 | -1.346 |
| Other Long Term Assets, Total | 0.081 | 0.063 | 0.045 | 0.045 | 0.039 |
| Total Current Liabilities | 7.583 | 9.066 | 8.492 | 5.434 | 7.606 |
| Payable/Accrued | 4.715 | 4.473 | 4.657 | 2.423 | 5.1 |
| Accrued Expenses | 1.989 | 3.713 | 2.985 | 2.213 | 1.72 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 13.083 | 14.968 | 14.817 | 12.12 | 14.73 |
| Total Long Term Debt | 1.347 | 1.579 | 1.682 | 1.719 | 1.846 |
| Long Term Debt | |||||
| Other Liabilities, Total | 4.153 | 4.323 | 4.643 | 4.967 | 5.278 |
| Total Equity | 94.85 | 103.407 | 113.986 | 125.916 | 135.308 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Additional Paid-In Capital | 303.641 | 302.202 | 300.75 | 299.271 | 297.815 |
| Retained Earnings (Accumulated Deficit) | -207.971 | -197.794 | -185.562 | -172.146 | -161.611 |
| Total Liabilities & Shareholders’ Equity | 107.933 | 118.375 | 128.803 | 138.036 | 150.038 |
| Total Common Shares Outstanding | 30.9713 | 30.7642 | 30.7209 | 30.7209 | 30.6828 |
| Short Term Investments | 87.396 | 89.321 | 105.108 | 113.815 | 127.503 |
| Other Equity, Total | -0.823 | -1.004 | -1.205 | -1.212 | -0.899 |
| Current Port. of LT Debt/Capital Leases | 0.879 | 0.88 | 0.85 | 0.798 | 0.786 |
| Capital Lease Obligations | 1.347 | 1.579 | 1.682 | 1.719 | 1.846 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -48.588 | -36.794 | -20.1 | -16.74 | -13.039 |
| Cash From Operating Activities | -39.026 | -30.259 | -17.705 | -8.571 | -10.313 |
| Cash From Operating Activities | 1.347 | 0.685 | 0.209 | 0.073 | 0.044 |
| Non-Cash Items | 7.207 | 5.733 | 2.583 | 4.627 | 1.192 |
| Changes in Working Capital | 1.008 | 0.117 | -0.397 | 3.469 | 1.49 |
| Cash From Investing Activities | 49.949 | -143.118 | -1.403 | -0.053 | -0.031 |
| Capital Expenditures | -0.321 | -2.026 | -1.206 | -0.053 | -0.031 |
| Cash From Financing Activities | -0.287 | 163.94 | 35.453 | 8.222 | 0.75 |
| Issuance (Retirement) of Stock, Net | 0.238 | 164.115 | 37.032 | 0.154 | 0 |
| Issuance (Retirement) of Debt, Net | -0.629 | -0.255 | 0.526 | 8.068 | 0.75 |
| Net Change in Cash | 10.636 | -9.437 | 16.345 | -0.402 | -9.594 |
| Other Investing Cash Flow Items, Total | 50.27 | -141.092 | -0.197 | ||
| Financing Cash Flow Items | 0.104 | 0.08 | -2.105 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.177 | -48.588 | -36.356 | -22.94 | -12.405 |
| Cash From Operating Activities | -11.736 | -39.026 | -29.452 | -22.649 | -10.75 |
| Cash From Operating Activities | 0.358 | 1.347 | 0.996 | 0.654 | 0.334 |
| Non-Cash Items | 1.277 | 7.207 | 5.555 | 3.829 | 1.988 |
| Changes in Working Capital | -3.194 | 1.008 | 0.353 | -4.192 | -0.667 |
| Cash From Investing Activities | 2.312 | 49.949 | 33.906 | 25.389 | 12.193 |
| Capital Expenditures | -0.151 | -0.321 | -0.321 | -0.071 | -0.019 |
| Cash From Financing Activities | -0.262 | -0.287 | -0.163 | 0 | 0.119 |
| Issuance (Retirement) of Stock, Net | 0 | 0.238 | 0.238 | 0.238 | 0.238 |
| Issuance (Retirement) of Debt, Net | -0.186 | -0.629 | -0.452 | -0.289 | -0.133 |
| Net Change in Cash | -9.686 | 10.636 | 4.291 | 2.74 | 1.562 |
| Other Investing Cash Flow Items, Total | 2.463 | 50.27 | 34.227 | 25.46 | 12.212 |
| Financing Cash Flow Items | -0.076 | 0.104 | 0.051 | 0.051 | 0.014 |
Sensei Biotherapeutics, Inc. Company profile
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The Company is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). It also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The Company is also engaged in developing a monoclonal antibody (mAb) therapy.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Sensei Biotherapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 82% to $36.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.68 to -$1.33.
| Industry: | Bio Therapeutic Drugs |
1405 Research Blvd, Suite 125
ROCKVILLE
MARYLAND 20850
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com